- Type / Class
- Equity / Common Stock
- Shares outstanding
- 15,766,370
- Total 13F shares
- 1,141,975
- Share change
- +495,464
- Total reported value
- $10,140,752
- Price per share
- $8.88
- Number of holders
- 17
- Value change
- +$4,400,867
- Number of buys
- 10
- Number of sells
- 3
Quarterly Holders Quick Answers
What is CUSIP 68232V884?
CUSIP 68232V884 identifies TRAW - Traws Pharma, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 68232V884:
Top shareholders of TRAW - Traws Pharma, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
|
Company |
3.8%
|
605,531
|
$3,560,522 | — | 30 Sep 2024 | |
| Viriom, Inc. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,645,100
|
$1,480,590 | — | 03 Apr 2024 | |
| Alyeska Investment Group, L.P. |
13D/G
|
— |
9.9%
|
302,252
|
$462,446 | $0 | 31 Dec 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.17%
|
26,722
|
$157,126 | — | 30 Sep 2024 | |
| Steven M. Fruchtman |
3/4/5
|
PRESIDENT, CHIEF EXECUTIVE OFF, Director |
—
mixed-class rows
|
121,014
mixed-class rows
|
$98,282 | — | 13 Mar 2024 | |
| BlackRock, Inc. |
13F
|
Company |
0.06%
|
9,956
|
$58,541 | — | 30 Sep 2024 | |
| Abraham N. Oler |
3/4/5
|
SVP Corp Dev & Gen Counsel |
—
mixed-class rows
|
96,197
mixed-class rows
|
$36,818 | — | 07 Feb 2022 | |
| Mark S. Gelder MD |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
82,667
mixed-class rows
|
$13,847 | — | 13 Mar 2023 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
2,138
|
$12,572 | — | 30 Sep 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
729
|
$4,287 | — | 30 Sep 2024 | |
| UBS Group AG |
13F
|
Company |
0%
|
630
|
$3,704 | — | 30 Sep 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
379
|
$2,229 | — | 30 Sep 2024 | |
| Vermillion & White Wealth Management Group, LLC |
13F
|
Company |
0%
|
205
|
$1,205 | — | 30 Sep 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
64
|
$376 | — | 30 Sep 2024 | |
| DANSKE BANK A/S |
13F
|
Company |
0%
|
7
|
$41 | — | 30 Sep 2024 | |
| Pacific Capital Wealth Advisors, Inc. |
13F
|
Company |
0%
|
2
|
$12 | — | 30 Sep 2024 | |
| Cornerstone Planning Group LLC |
13F
|
Company |
—
class O/S missing
|
1
|
$5 | — | 30 Sep 2024 | |
| Luba Greenwood |
3/4/5
|
Director |
—
class O/S missing
|
164,000
|
— | — | 16 Sep 2024 | |
| Victor M. Moyo |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
class O/S missing
|
125,000
|
— | — | 02 Oct 2023 | |
| James J. Marino |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Jerome Groopman |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Peter Atadja |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 | |
| Viren Mehta |
3/4/5
|
Director |
—
class O/S missing
|
66,468
|
— | — | 10 Aug 2023 |
Institutional Holders of Traws Pharma, Inc. - Common Stock (TRAW) as of Q4 2024
As of 31 Dec 2024,
Traws Pharma, Inc. - Common Stock (TRAW) was held by
17 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,141,975 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, PERCEPTIVE ADVISORS LLC, Alyeska Investment Group, L.P., Ikarian Capital, LLC, Vestal Point Capital, LP, GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, and MILLENNIUM MANAGEMENT LLC.
This page lists
17
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
10
Q4 2024 holders
17
Holder diff
7
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 Value $ | Q4 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.